JP2025513774A - Ｍｃｌ－１アンタゴニストの塩形態及び溶媒和物 - Google Patents

Ｍｃｌ－１アンタゴニストの塩形態及び溶媒和物 Download PDF

Info

Publication number
JP2025513774A
JP2025513774A JP2024558381A JP2024558381A JP2025513774A JP 2025513774 A JP2025513774 A JP 2025513774A JP 2024558381 A JP2024558381 A JP 2024558381A JP 2024558381 A JP2024558381 A JP 2024558381A JP 2025513774 A JP2025513774 A JP 2025513774A
Authority
JP
Japan
Prior art keywords
crystalline form
xrpd pattern
peaks
amg176
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513774A5 (enExample
Inventor
モリソン，ヘンリー
テッドロウ，ジェイソン・エス
ペアレント，スティーブン・ディー
ジョンソン，コートニー
ヒューストン，トラビス
ベビル，メラニー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2025513774A publication Critical patent/JP2025513774A/ja
Publication of JP2025513774A5 publication Critical patent/JP2025513774A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2024558381A 2022-04-05 2023-04-05 Ｍｃｌ－１アンタゴニストの塩形態及び溶媒和物 Pending JP2025513774A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263327659P 2022-04-05 2022-04-05
US63/327,659 2022-04-05
PCT/US2023/017504 WO2023196360A1 (en) 2022-04-05 2023-04-05 Salt forms and solvates of mci-1 antagonists

Publications (2)

Publication Number Publication Date
JP2025513774A true JP2025513774A (ja) 2025-04-30
JP2025513774A5 JP2025513774A5 (enExample) 2026-04-10

Family

ID=86386785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024558381A Pending JP2025513774A (ja) 2022-04-05 2023-04-05 Ｍｃｌ－１アンタゴニストの塩形態及び溶媒和物

Country Status (9)

Country Link
US (1) US12351588B2 (enExample)
EP (1) EP4504737A1 (enExample)
JP (1) JP2025513774A (enExample)
AU (1) AU2023249146A1 (enExample)
CA (1) CA3254998A1 (enExample)
MX (1) MX2024012192A (enExample)
TW (1) TW202404983A (enExample)
UY (1) UY40217A (enExample)
WO (1) WO2023196360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1

Also Published As

Publication number Publication date
CA3254998A1 (en) 2023-10-12
MX2024012192A (es) 2024-11-08
US20230312602A1 (en) 2023-10-05
TW202404983A (zh) 2024-02-01
US12351588B2 (en) 2025-07-08
AU2023249146A1 (en) 2024-10-10
WO2023196360A1 (en) 2023-10-12
EP4504737A1 (en) 2025-02-12
UY40217A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
CN107873029B (zh) 依鲁替尼与羧酸的共晶体
ES2985767T3 (es) Formas en estado sólido de rucaparib y de sales de rucaparib
JP2014511336A (ja) アファチニブの新規塩及び多形形態
JP2026031971A (ja) Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法
CZ2015384A3 (cs) Pevné formy Tenofovir alafenamidu
JP2025513774A (ja) Ｍｃｌ－１アンタゴニストの塩形態及び溶媒和物
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
JP2025505142A (ja) ムリザトクラクス（ａｍｇ３９７）の結晶塩及び溶媒和物形態
US20250115622A1 (en) Crystalline Forms Of An MCL-1 Inhibitor
CN108473507A (zh) 噻吩并嘧啶化合物的结晶形式
US20250002453A1 (en) Pharmaceutically acceptable salt of eliglustat and crystal form thereof
TWI900603B (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
JP6907439B2 (ja) チエノピリミジン化合物の塩酸塩の結晶形
ES3010375T3 (en) Crystalline forms of 4-amino-n-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide, methods of preparation, and uses thereof
AU2022234309B2 (en) Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
CZ2015834A3 (cs) Pevná forma dapagliflozinu
US20230286900A1 (en) Polymorphic forms of (r)-oxybutynin hydrochloride
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
HK40095644A (zh) 多重酪胺酸激酶抑制剂的结晶盐、其制备方法及用途
NZ743660A (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
CN108718526A (zh) (3z)-3-{[(4-{甲基[(4-甲基哌嗪-1-基)乙酰基]氨基}苯基)氨基](苯基)亚甲基}-2-氧代-2,3-二氢-1h-吲哚-6-甲酸甲酯盐的结晶变态和其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260402